We are pleased to note that Rheostat, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, has announced the closing of a $23 million Series A financing. Read the full press release here: https://t.co/io7OKH5Ys7
“The nice thing about a platform like this, and going against undruggable targets, is that you can go across all sorts of indications,” said CEO Solomon, who helped found Epizyme and served as its VP of discovery: https://t.co/12QOP7UGrO
We're delighted to be working with the Dementia Discovery Fund (@TheDDFund) to launch D3A, an exciting accelerator programme that will move dementia science closer to the clinic.
Find out more: https://t.co/ll6u8BJ4Hj
Dementia Discovery Fund launches new research accelerator partnership with the @UKDRI at inaugural Annual Forum for Dementia. D3A will support important research projects with potential to create meaningful new medicines for dementia https://t.co/JMATv28nig
Such an honour to speak at the @TheDDFund reception tonight - celebrating fundraising a staggering £250m in this unique collaboration to defeat #dementia
We're delighted to see that the NIH is funding a broad range of fresh ideas to help tackle Alzheimer's disease https://t.co/7Y22iNOeuZ #Alzheimers@sciencemagazine
Since we launched in October 2015, the #DDF has made significant progress building an initial portfolio of 16 investments in drug discovery companies and projects predominantly in the UK and US #dementia. Find out more about us by visiting our website https://t.co/VU1YQh17g0
The #DDF can provide guidance and hands-on support to help companies to develop innovative drugs for dementia patients. To find out more how we can help you, visit our website #dementiaresesearch#dementia#alzheimers https://t.co/VU1YQh17g0
#DDF invests in truly novel, early-stage projects starting from target identification, and explore novel biological insights for translation into disease-modifying drugs for #dementia and #alzheimers
The #DDF can provide guidance and hands-on support to help companies to develop innovative drugs for dementia patients. To find out more how we can help you, visit our website #dementiaresesearch#dementia#alzheimers https://t.co/VU1YQh17g0
“One of the key goals of the DDF is to bring diversity to the range of approaches that we’re going to use to attack dementia” Tetsu Maruyama, Chief Scientific Officer of the DDF.
The DDF does not only invest in existing companies, but also initiates projects to help create new drug discovery companies designed to explore new approaches to tackling #dementia. Find out more about how you can work with us
https://t.co/VU1YQh17g0
Did you know that dementia has higher health and social care costs (£11.9bn) than cancer (£5.0bn) and chronic heart disease (£2.5bn) combined.
Click here for more revealing statistics: https://t.co/G5ryAL0FbB
We would love to hear from scientists, researchers and companies developing novel therapies for Dementia, who need funding and help. You can get in touch with us through our website
https://t.co/VU1YQh17g0